Jul 26, 2016 by Brian Orelli, PhD3 Things to Watch as Celgene Corporation Reports EarningsIncreasing Revlimid sales is key, but don't forget about Otezla.
Jul 26, 2016 by Brian Orelli, PhDWhy Cryolife Inc's Shares Turned Hot TodayAfter doing some adjustments, the healthcare company's earnings look good.
Jul 22, 2016 by Brian Orelli, PhDWhy athenahealth, Inc Shares Sank TodayDouble-digit revenue growth fell short of expectations.
Jul 22, 2016 by Brian Orelli, PhDBiogen Inc: How Double-Digit Growth Got TrumpedThe biotech's CEO turns in his resignation notice.
Jul 21, 2016 by Brian Orelli, PhDSorry, You Can't Buy This Hot Biotech -- At Least Not DirectlyFortunately, privately held Moderna Therapeutics has multiple partnerships with public companies.
Jul 20, 2016 by Brian Orelli, PhDWhy Progenics Pharmaceuticals, Inc. Shares Soared TodayThe biotech scored FDA approval for the oral version of its opioid-induced constipation drug, Relistor.
Jul 20, 2016 by Brian Orelli, PhDHow Natus Medical Inc. Got Back on TrackThe medical device and services company produced a relatively strong second quarter and raises guidance.
Jul 18, 2016 by Brian Orelli, PhD3 Things to Watch As Natus Medical Inc Reports EarningsThe medical device and services company is scheduled to report earnings on Wednesday, July 20.
Jul 5, 2016 by Brian Orelli, PhDWhy XBiotech Inc. Fell 33% TodayWithout much to go on, investors wonder how well the biotech's colon-cancer drug Xilonix works.
Jul 1, 2016 by Brian Orelli, PhDWhy Alnylam Pharmaceuticals, Inc. Jumped 10.7% on FridayPositive phase 2 data bodes well for the biotech.
Jul 1, 2016 by Brian Orelli, PhDAn Overnight Double! Could These Drugmakers Be Next?The PARP inhibitor space is hot.
Jul 1, 2016 by Brian Orelli, PhDThis $6.7 Billion Drug Just Keeps GrowingSales of the Celgene's cancer drug Revlimid should increase thanks to J&J's Darzalex.
Jun 30, 2016 by Brian Orelli, PhD141 Reasons to Love Biotech StocksDespite recent troubles, the promising sector has had a good run.
Jun 29, 2016 by Brian Orelli, PhDEsperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019"The FDA leaves the biotech hanging.
Jun 28, 2016 by Brian Orelli, PhDWhy Endo International plc Patented a Higher Stock PriceA patent for a decades-old drug.
Jun 27, 2016 by Brian Orelli, PhDRegulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?Another case of jaundice for RG-101.
Jun 23, 2016 by Brian Orelli, PhDBetter Buy: Biogen Inc. vs. Celgene CorporationA battle of the big biotechs.
Jun 23, 2016 by Brian Orelli, PhD2 Words That Could Bring Down the Entire Prescription Drug IndustryA little-known provision allows the government to end patents on a drug.
Jun 22, 2016 by Brian Orelli, PhDWhy Emergent BioSolutions Inc. Procured a Lower Price TodayA contract with the U.S. government falls short of expectations.
